New combo therapy aims to personalize throat cancer treatment
NCT ID NCT07428148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for people with a certain type of throat cancer that is not low-risk. Participants first receive a combination of chemotherapy, immunotherapy, and a special type of radiation called lattice radiotherapy. Then, based on how much the tumor shrinks, they get either a shorter or longer course of standard chemoradiation. The goal is to see if this personalized plan is safe and effective. About 60 people will take part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carboplatin, paclitaxel, pembrolizumab, and lattice radiotherapy
What this could lead to
If successful, this could lead to a more personalized, effective treatment for throat cancer that reduces side effects by tailoring radiation dose to how well the tumor responds.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and the optimal dose is still being determined.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
New York, New York, 10016, United States